Calixcoca
Experimental Brazilian vaccine for cocaine and crack addiction.
Wikipedia / Wikimedia Commons
Calixcoca is an experimental vaccine developed to treat addiction to cocaine and crack cocaine. It has been under development since 2015 by the Federal University of Minas Gerais (UFMG) in Brazil, and it won the Euro Health Innovation Award in October 2023.
- field
- Addiction treatment / Vaccine research
- nationality
- Brazilian
- known_for
- Experimental vaccine against cocaine and crack cocaine addiction
- developer
- Federal University of Minas Gerais (UFMG)
- lead_researcher
- Frederico Garcia
- active_ingredient
- V4N2 molecule
Lore & Background
The vaccine was created by a team led by Frederico Garcia, a professor in the Department of Mental Health at the UFMG Faculty of Medicine. Garcia stated that the motivation for the work came from seeing the suffering of pregnant women addicted to cocaine who arrived at the university's outpatient clinic. The active ingredient of the vaccine, V4N2, was designed and synthesized by the synthesis group headed by professor Ângelo de Fátima from the Department of Chemistry at UFMG.
During the pre-clinical phase, investment was provided by the National Council for Scientific and Technological Development (CNPq) and the Minas Gerais Research Support Foundation (Fapemig). On June 1, 2023, the city of São Paulo announced an initial investment of R$4 million to accelerate vaccine research.
Unlike other anti-cocaine vaccines, Calixcoca is not protein-based. The V4N2 molecule stimulates the immune system to produce antibodies that bind to cocaine molecules in the blood. Cocaine molecules bound to these antibodies are too large to pass the blood-brain barrier, preventing them from reaching the brain and causing psychological effects.
Reader's Guide
Calixcoca represents a novel approach to treating cocaine and crack cocaine addiction, using a non-protein-based molecule (V4N2) to stimulate antibody production. Pre-clinical studies in mice demonstrated the production of anti-cocaine antibodies, making the drug's effects imperceptible, reducing spontaneous abortions, and resulting in healthier pups with greater resistance to the drug. The vaccine's development, led by Brazilian researchers at UFMG, highlights a potential breakthrough in addiction medicine. Its selection as a finalist and winner of the Euro Health Innovation Award in 2023 underscores its promise, though it remains experimental. The investment from São Paulo and earlier funding from CNPq and Fapemig indicate growing support for this approach, which could offer a new tool to combat cocaine addiction by blocking the drug's psychoactive effects.
Did You Know?
- Calixcoca won the Euro Health Innovation Award in October 2023.
- The vaccine's active ingredient, V4N2, was designed and synthesized by a group led by professor Ângelo de Fátima.
- Pre-clinical studies in mice showed the vaccine reduced spontaneous abortions and led to healthier pups.
- Unlike other anti-cocaine vaccines, Calixcoca is not protein-based.
Frequently Asked Questions
What is Calixcoca?
Calixcoca is a Brazilian experimental vaccine designed to treat addiction to cocaine and crack cocaine. It works by targeting the V4N2 molecule as its active ingredient to help patients overcome dependence.
Who developed Calixcoca and where?
The vaccine was developed at the Federal University of Minas Gerais (UFMG) in Brazil, with Frederico Garcia serving as the lead researcher. Development has been ongoing since 2015.
What is the active ingredient in Calixcoca?
The vaccine's active component is a molecule designated V4N2, which is the key element responsible for its therapeutic effect against cocaine and crack addiction.
What major award has Calixcoca received?
In October 2023, Calixcoca was recognized with the Euro Health Innovation Award, highlighting its potential as a breakthrough in addiction-treatment vaccine research.
Why is Calixcoca considered important in the field of addiction treatment?
It represents one of the first vaccine-based approaches specifically targeting cocaine and crack cocaine dependence, offering a novel therapeutic pathway beyond traditional interventions. Its recognition with the Euro Health Innovation Award in 2023 underscored its significance in global health innovation.
More in Brazilian inventions 1-24
Spotted an error? Know more?
This is a living reference — every entry is fact-audited, and reader corrections feed straight into our audit queue. Suggest an edit · See this site's audit record